CO2018003558A2 - Método de cristalización y biodisponibilidad - Google Patents

Método de cristalización y biodisponibilidad

Info

Publication number
CO2018003558A2
CO2018003558A2 CONC2018/0003558A CO2018003558A CO2018003558A2 CO 2018003558 A2 CO2018003558 A2 CO 2018003558A2 CO 2018003558 A CO2018003558 A CO 2018003558A CO 2018003558 A2 CO2018003558 A2 CO 2018003558A2
Authority
CO
Colombia
Prior art keywords
crystallization
bioavailability method
bioavailability
characterization
humans
Prior art date
Application number
CONC2018/0003558A
Other languages
English (en)
Spanish (es)
Inventor
Mazen Hanna
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58289727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018003558(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CO2018003558A2 publication Critical patent/CO2018003558A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2018/0003558A 2015-09-18 2018-04-04 Método de cristalización y biodisponibilidad CO2018003558A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220404P 2015-09-18 2015-09-18
PCT/US2016/052492 WO2017049294A1 (en) 2015-09-18 2016-09-19 Crystallization method and bioavailability

Publications (1)

Publication Number Publication Date
CO2018003558A2 true CO2018003558A2 (es) 2018-07-19

Family

ID=58289727

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003558A CO2018003558A2 (es) 2015-09-18 2018-04-04 Método de cristalización y biodisponibilidad

Country Status (12)

Country Link
US (1) US20190083407A1 (enExample)
EP (1) EP3362071A4 (enExample)
JP (1) JP2018527392A (enExample)
KR (1) KR20180053384A (enExample)
CN (1) CN108601791A (enExample)
AU (1) AU2016324482A1 (enExample)
CA (1) CA2997378A1 (enExample)
CL (1) CL2018000705A1 (enExample)
CO (1) CO2018003558A2 (enExample)
MX (1) MX2018002627A (enExample)
PE (1) PE20180931A1 (enExample)
WO (1) WO2017049294A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN108440449B (zh) * 2018-04-17 2021-05-07 中国海洋大学 一种氢氯噻嗪与脯氨酸的共晶及其制备方法
CN108558791B (zh) * 2018-06-08 2021-05-07 中国海洋大学 一种乙酰唑胺与脯氨酸的共晶及其制备方法
CN108570051B (zh) * 2018-07-20 2021-02-02 中国科学院上海药物研究所 呋塞米-氨苯蝶啶盐、晶型i及其制备方法和应用
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
CN109568284B (zh) * 2018-12-29 2020-04-24 广东中润药物研发有限公司 一种替诺福韦艾拉酚胺肠溶片及其制备方法
CN109776430B (zh) * 2019-02-01 2022-05-13 福建农林大学 一种磺胺二甲嘧啶共晶及其制备方法
GB201907591D0 (en) * 2019-05-29 2019-07-10 Eolas Res Limited Composition and use
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN110372575A (zh) * 2019-07-10 2019-10-25 复旦大学 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用
CN111053755B (zh) * 2019-12-31 2022-03-29 金日制药（中国）有限公司 一种高渗透性的头孢克肟胶囊制剂制备方法
CN116917267B (zh) * 2021-01-28 2025-08-12 Imd制药公司 包含卡莫司他及氯硝柳胺的共晶、包含其的药物组合物及其制备方法
CN113181179A (zh) * 2021-04-08 2021-07-30 深圳市泰力生物医药有限公司 一种二氢吡啶类钙拮抗剂盐组合物及其制备方法和应用
KR102544543B1 (ko) * 2021-04-29 2023-06-16 대봉엘에스 주식회사 L,d-엘도스테인의 개별적 공결정화물
US20260224490A1 (en) * 2023-01-11 2026-08-06 Board Of Regents, The University Of Texas System Co-crystals with thin-film freeze-drying process to enhance delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
ES2322592T3 (es) * 2003-07-03 2009-06-23 Teva Pharmaceutical Industries Ltd. Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion.
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
KR20120105738A (ko) * 2011-03-16 2012-09-26 현대약품 주식회사 장용코팅된 경구용 제제
PL2849758T3 (pl) * 2012-05-14 2018-08-31 Antecip Bioventures Ii Llc Kompozycje zawierające kwas zoledronowy lub pokrewne związki do uśmierzania bólu zapalnego i stanów powiązanych
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US8802658B2 (en) * 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US20140348916A1 (en) * 2014-08-11 2014-11-27 Antecip Bioventures Ii Llc Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer

Also Published As

Publication number Publication date
EP3362071A4 (en) 2019-07-17
CL2018000705A1 (es) 2018-08-24
JP2018527392A (ja) 2018-09-20
WO2017049294A1 (en) 2017-03-23
CA2997378A1 (en) 2017-03-23
AU2016324482A1 (en) 2018-03-29
MX2018002627A (es) 2018-12-17
CN108601791A (zh) 2018-09-28
EP3362071A1 (en) 2018-08-22
PE20180931A1 (es) 2018-06-08
KR20180053384A (ko) 2018-05-21
US20190083407A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
ES2820879R1 (es) Composiciones para la liberación controlada de ingredientes activos y métodos de preparación de las mismas
IL275639A (en) Formulation for RNA administration
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
IL257371A (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
AU2016219653A1 (en) Crystallization Method and Bioavailability
DK3727555T3 (da) Oral delivery of active drug substances
IL253619A0 (en) Encapsulation of high potency active agents
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
MA42991A (fr) Stabilisation de compositions pharmaceutiques de camptothécine
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
MX385925B (es) Oritavancina de alta pureza y método para producir la misma.
JO3683B1 (ar) صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
ZA201806357B (en) Protein based excipient for active pharmaceutical ingredients
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3362048A4 (en) COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS
DK3168214T3 (da) Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer
IL271596A (en) Preparations for administering drugs and methods of using them
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX391186B (es) Metodo para preparar un sistema de suministro de uno o mas ingredientes activos en una composicion comestible.
MX384254B (es) Formulaciones para mejorar la eficacia de farmacos hidrofobicos.
IL252579B (en) History of methyl-(1h-pyrazolo-4-yl-)-3-methyl-1h-pyrazolo[3,4-d]pyrimidine and pharmaceutical preparations containing them